The Long Road to an Effective Vaccine for Meningococcus Group B (MenB).

about

Meningococcal serogroup B vaccine in Italy: state-of-art, organizational aspects and perspectives Adolescent Vaccination Strategies: Interventions to Increase Coverage.The next chapter for group B meningococcal vaccines.

P2860

Q26770702-CE5614B9-C3B9-475B-A1AE-791CFF70DBBD Q30251432-8F4238CC-8293-4916-B3AD-6C0E46CED43A Q38677309-6EB11E00-87B1-4D3E-BC85-406F30ECF5C8

P2860

The Long Road to an Effective Vaccine for Meningococcus Group B (MenB).

Item

http://www.wikidata.org/entity/Q38335257

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

The Long Road to an Effective Vaccine for Meningococcus Group B (MenB).

@en

type

Item

label

The Long Road to an Effective Vaccine for Meningococcus Group B (MenB).

@en

prefLabel

The Long Road to an Effective Vaccine for Meningococcus Group B (MenB).

@en

P1476

The Long Road to an Effective Vaccine for Meningococcus Group B (MenB).

@en

P2093

Michael W Shea

http://www.w3.org/2001/XMLSchema#string

P2860

Complete Genome Sequence of Neisseria meningitidis Serogroup B Strain MC58

NadA, a novel vaccine candidate of Neisseria meningitidis

Lyme borreliosis

Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans

The transposon-like Correia elements encode numerous strong promoters and provide a potential new mechanism for phase variation in the meningococcus.

Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity

Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa

Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010

Three doses of an experimental detoxified L3-derived lipooligosaccharide meningococcal vaccine offer good safety but low immunogenicity in healthy young adults.

P304

53-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S2049-0801(13)70037-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25628885

http://www.w3.org/2001/XMLSchema#string

P932

4306095

http://www.w3.org/2001/XMLSchema#string

The Long Road to an Effective Vaccine for Meningococcus Group B (MenB).

about

P2860

P2860

The Long Road to an Effective Vaccine for Meningococcus Group B (MenB).

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932